You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1925 Results
Drug
Other Name(s): Unituxin®
Jun 2023
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
ODB Limited Use
    anagrelide
Apr 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
ODB - General Benefit
    procarbazine
ODB - General Benefit
    prednisone
May 2019
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Metastatic Merkel Cell Carcinoma
Jan 2025
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
May 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib - For the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible
Dec 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
High Cost Therapy Funding Program
    Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Jun 2019

Pages